Mimedx Group, Inc · NASDAQ:MDXG
Mimedx — Q2 2025 Earnings Presentation
22 slides from Mimedx's earnings presentation, Jul 30, 2025
Slide 1: August 2025 Investor Presentation
August 2025 Investor Presentation
Slide 2: Disclaimer & Cautionary Statements
Disclaimer & Cautionary Statements This presentation and our earnings call includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materiall
Slide 3: A Pioneer and Leader Focused on Helping Humans Heal
A Pioneer and Leader Focused on Helping Humans Heal Investor Presentation – August 2025 3 Over a decade of experience helping clinicians manage chronic and other hard-to-heal wounds Leading the industry with innovative products and robust supporting clinical data Poised to capitalize on favorable ma
Slide 4: The Most Comprehensive End-to-End Product Ecosystem
The Most Comprehensive End-to-End Product Ecosystem 4Investor Presentation – August 2025 The most studied portfolio of placental products with 50+ clinical & scientific publications and over 300 million payer covered lives. New product innovations leading to untapped opportunities for growth, includ
Slide 5: Expansive Donor Network & IP Power Our Product Offering
Expansive Donor Network & IP Power Our Product Offering 5Investor Presentation – August 2025 National Network of Birthing Center Partners Ample Placental Supply and Manufacturing Capabilities to Support Continued Growth and Industry Demand Expectant Mothers Introduced to Donation Program Consent for
Slide 6: Addressing a Large and Unmet Need for Healing Solutions
Addressing a Large and Unmet Need for Healing Solutions Investor Presentation – August 2025 6 Favorable Demographic Trends Increasing Clinical Evidence Expanding Potential For Products 1) Sen CK. Human Wound and Its Burden: Updated 2022 Compendium of Estimates. Adv Wound Care (New Rochelle). 2023;12
Slide 7: The Patient Journey in Wound Care
The Patient Journey in Wound Care 7Investor Presentation – August 2025 Private Office Home Health Mobile Health Nursing Facility Assisted Living Facility Wound Care Clinic Hospital Outpatient Hospital Inpatient …and other care settings Mohs surgery Burn/Trauma DFU VLU Limb Salvage Dehiscence Acute W
Slide 8: Surgical Studies Underway Highlight Product Versatility
Surgical Studies Underway Highlight Product Versatility 8Investor Presentation – August 2025 Published May 2025 Journal of Drugs in Dermatology Manuscript Pending RCT Enrollment Underway RCT Enrollment Underway Generating Clinical Data in Numerous Surgical Disciplines Incorporating Use of MIMEDX Pro
Slide 9: Highlights from Our Expanding Product Portfolio
Highlights from Our Expanding Product Portfolio 9Investor Presentation – August 2025 Innovative Wound Products Growing Surgical Offering Expanding into Xenografts
Slide 10: Large Wound Care Business with Growing Surgical Footprint
Large Wound Care Business with Growing Surgical Footprint 10Investor Presentation – August 2025 $0 $50,000 $100,000 $150,000 $200,000 $250,000 $0 00 s LTM Surgical Performance LTM @ Q2:24 LTM @ Q2:25 $0 $50,000 $100,000 $150,000 $200,000 $250,000 $0 00 s LTM Wound Performance LTM @ Q2:24 LTM @ Q2:25
Slide 11: Financial Highlights
$50MM $70MM $86MM $88MM $100MM Q2:24 Q3:24 Q4:24 Q1:25 Q2:25 Financial Highlights 11Investor Presentation – August 2025 LTM GAAP Gross Margin 81% LTM Net Sales $364MM +7% year-over-year LTM GAAP Net Income $32MM LTM Adjusted EBITDA1 $79MM 22% of net sales LTM Free Cash Flow $57MM Net Cash Balance $1
Slide 12: Medicare Reform Expected to Transform Category in 2026
Medicare Reform Expected to Transform Category in 2026 Investor Presentation – August 2025 12 LCDs in all MAC regions are scheduled for implementation on Jan. 1, 2026, requiring RCT data for coverage of skin substitutes PFS and OPPS proposed rules scheduled for implementation on Jan. 1, 2026, aligni
Slide 13: Strategic Priorities Position Us to Win in 2025 & Beyond
Strategic Priorities Position Us to Win in 2025 & Beyond Investor Presentation – August 2025 13 Innovate & Diversify Product Portfolio to Maximize Growth Develop & Deploy Programs to Expand Surgical Footprint Enhance Customer Intimacy Enrollment continues for EPIEFFECT RCT with plans for interim rep
Slide 14: Experienced, Skillful Leadership Team Executing Strategy
Experienced, Skillful Leadership Team Executing Strategy Investor Presentation – August 2025 Prior Roles Include: Management Team with Track Record of Success in MedTech Joe Capper Chief Executive Officer Doug Rice Chief Financial Officer Butch Hulse Chief Administrative Officer & General Counsel Ki
Slide 15: Conclusion
Conclusion Investor Presentation – August 2025 15 1 2 3 4 Large & expanding addressable markets Maturing reimbursement & regulatory landscape 5 Competitive advantage with innovative products, defensible IP and proprietary technology Strong & improving financial profile & balance sheet Experienced &
Slide 16: Appendix
Appendix 16
Slide 17: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP Measures In addition to our GAAP results, we provide certain non-GAAP measures including Adjusted EBITDA, related margins, Free Cash Flow, Adjusted Gross Profit, Adjusted Gross Margin and Adjusted Net Income. • Adjusted EBITDA consists of GAAP net income excluding: (i) dep
Slide 18: Reconciliation of Non-GAAP Measures (cont.)
Reconciliation of Non-GAAP Measures (cont.) • Each of the adjustments to reconcile Adjusted Net Income to GAAP net income affect individual financial statement captions which are reflected in our consolidated statements of operations, including gross profit. Adjusted Gross Profit is therefore define
Slide 19: Adjusted Gross Profit & Adjusted Gross Profit Margin
Adjusted Gross Profit & Adjusted Gross Profit Margin 19 Three Months Ended June 30, 2024June 30, 2025Amounts (in millions) $ 72.4$ 79.9GAAP gross profit 0.42.5Amortization of acquisition-related intangible assets $ 72.8$ 82.4Adjusted Gross Profit 83.5 %83.6 %Adjusted Gross Profit Margin
Slide 20: Adjusted EBITDA - QTD
Adjusted EBITDA - QTD 20 June 30, 2024June 30, 2025Amounts (in millions) for the three months ended $ 17.6$ 9.6Net income 0.60.6Depreciation expense 0.62.6Amortization of intangible assets —(0.7)Interest income, net 5.63.4Income tax provision 4.14.8Stock-based compensation expense 0.62.5Strategic le
Slide 21: Adjusted Net Income and Adjusted EPS - QTD
Adjusted Net Income and Adjusted EPS - QTD 21 June 30, 2024June 30, 2025Amounts (in millions) for the three months ended $ 17.6$ 9.6Net income - GAAP 0.42.5Amortization of acquisition-related intangible assets 0.62.5Strategic legal and regulatory expenses (9.7)—Investigation, restatement and related
Slide 22: Free Cash Flow
Free Cash Flow 22 Three months ended June 30, 2024June 30, 2025Amounts in millions $ 21.8$ 14.4Cash flows from operating activities (0.1)(0.2)Purchases of equipment $ 21.7$ 14.2Free Cash Flow